期刊文献+

呼吸道合胞病毒逃逸株对单克隆抗体预防的抵抗 被引量:5

Escape mutant of respiratory syncytial virus resists palivizumab prophylaxis
原文传递
导出
摘要 目的 探讨体外筛选的呼吸道合胞病毒抗体逃逸株生长特性、F蛋白免疫反应性及在棉鼠体内对抗体免疫预防的抵抗 ,旨在证实用单克隆抗体免疫预防的负面效应 ,为今后临床可能出现的抗体逃逸株提供线索。方法 呼吸道合胞病毒 (RSV)A2株在逐渐升高的Palivizumab(PZ)浓度环境中连续传代 5次并经单噬斑纯化后获得PZ逃逸株MP4。用RT PCR法扩增A2及MP4全长F基因并自动测序 ;用微量中和试验鉴定MP4在体外对PZ中和反应的抗性 ;用Westernblot鉴定其F蛋白免疫反应性的变化 ;最后在棉鼠模型内观察PZ预防A2和MP4感染的效果。结果 与A2母株比较 ,MP4于F基因 82 8位核苷酸发生突变 (A→T) ,导致 2 72位推导氨基酸由赖氨酸变为甲硫氨酸。MP4在体外及在棉鼠肺内的生长能力无明显改变。MP4F蛋白虽仍可表达于受感染细胞膜上 ,但不再被PZ识别。动物实验证实 ,即使大剂量PZ亦不能预防MP4感染。结论 体外筛选的PZ逃逸株在棉鼠模型体内对同一抗体的免疫预防具有极强的抗性 ,类似情况是否会在人体内发生及是否会导致严重后果尚有待进一步研究。 Objective Palivizumab (PZ), a humanized monoclonal antibody against RSV fusion protein, is prophylactically given in certain high risk children. Expanding use in children and in individuals with ineffective cell mediated viral clearing will provide opportunities for the emergence of antibody resistant viruses. The ability of PZ resistant virus to evade PZ prophylaxis was evaluated in cotton rats. Methods A2 RSV was passed in culture in increasing PZ concentrations (0.4 to 40 μg/ml) and the resulting virus was characterized from a single plaque (MP4). Antigenecity, resistance to PZ in vitro and in vivo were assessed by use of Western blot, microneutralization assay and prophylactic experiment in cotton rats, respectively. Results MP4 was 100 fold less susceptible to PZ neutralization as compared to A2. The F protein gene of MP4 had a nucleotide substitution (base 828 A to T) that resulted in a coding change (amino acid 272 Lys to Met). Cotton rats were given prophylactic PZ and challenged with virus intranasally. The MP4 challenged rats had no reduction in lung viral titers as compared to rats that did not receive PZ. The A2 challenged rats revealed the expected PZ protection against RSV replication. Conclusion A virus resistant to PZ in culture was also resistant to the prophylactic effect of PZ in cotton rats. Whether PZ resistant viruses will occur in humans and result in clinical consequences is unknown.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2005年第3期222-226,共5页 Chinese Journal of Microbiology and Immunology
  • 相关文献

参考文献17

  • 1The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 1998, 102(3 Pt 1); 531-537.
  • 2Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus in high risk infants: a concensus opinin. Pediartics, 1999, 18: 223-231.
  • 3Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis, 2001, 184(3): 350-354.
  • 4Anderson LJ, Hierholzer JC, Bingham PG, et al. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol, 1985, 22(6): 1050-1052.
  • 5Anderson K, Stott EJ, Wertz GW. Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage. J Gen Virol, 1992, 73: 1177-1188.
  • 6Lopez JA, Bustos R, Portela A, et al. A point mutation in the F1 subunit of human respiratory syncytial virus fusion glycoprotein blocks its cell surface transport at an early stage of the exocytic pathway. J Gen Virol, 1996, 77: 649-660.
  • 7Collins PL, Mclntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, ed. Fields Virology, Third Edition, Philadelphia: Lippincott-Raven, 1996, 1313-1351.
  • 8Domingo E, Holland JJ. High error rates, population equilibrium, and evolution of RNA replication systems. RNA genetics, Vol Ⅲ, CRC Press, Inc, Boca Raton, Fla. 1998.
  • 9Domingo E, Holland J. Mutation rates and rapid evolution of RNA virus. In: The Evolutionary Biology of Viruses. Morse S, (ed). Raven Press: New York, 1994: 161-184.
  • 10Gaddum RM, Cook RS, Wyld SG, et al. Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virus infection. J Gen Virol, 1996, 77: 1239-1248.

同被引文献69

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部